Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Eso, Yuji, Nakano, Shigeharu, Mishima, Masako, Arasawa, Soichi, Iguchi, Eriko, Nakamura, Fumiyasu, Takeda, Haruhiko, Takai, Atsushi, Takahashi, Ken, Taura, Kojiro, Seno, Hiroshi
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016578/
https://ncbi.nlm.nih.gov/pubmed/31877859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados